CJC-1295 with DAC vs No DAC: Structural and Kinetic Differences

CJC-1295 with DAC vs No DAC: Structural and
Kinetic Differences

The most important
distinction between CJC-1295 with DAC and material sold as “CJC-1295
No DAC” is chemical identity, not a marketing promise about
duration. In the original literature, CJC-1295 is a tetrasubstituted
hGRF(1-29) analogue carrying a maleimido group that enables covalent
albumin binding. “No DAC” is a later commercial shorthand for a
modified GRF(1-29)-type peptide without that albumin-binding group.

Because the names
are used inconsistently online, a laboratory should resolve the
sequence/form, linker status, expected mass, HPLC profile and
mass-spectrometric identity before interpreting any kinetic
literature.

Figure
1. CJC-1295 DAC versus no-DAC identity framework comparing
albumin-binding linker, sequence/form, HPLC profile, MS identity and
batch evidence.

Quick comparison

Attribute	CJC-1295 with DAC	“CJC-1295 No DAC”
Literature naming	CJC-1295 in the original Jette/Teichman literature	Commercial shorthand; exact supplier identity must be resolved
Albumin-binding design	Maleimido functionality designed for covalent albumin binding	No DAC maleimido functionality
Primary identity check	Chemical form/linker + expected mass + MS	Exact modified GRF sequence/form + expected mass + MS
HPLC role	Method-specific purity/profile	Method-specific purity/profile
Kinetic literature	Long-exposure data exist for the DAC compound	Do not transfer DAC human half-life values to a no-DAC material

Why the DAC group changes the entity

Jette and colleagues
designed CJC-1295 as a maleimido derivative of a modified hGRF(1-29)
analogue. The maleimide reacts with a free thiol on albumin,
producing a covalent bioconjugate. That design changes the molecular
species present in an albumin-containing system and is the
mechanistic basis for the prolonged exposure reported in the original
animal and human studies.

A no-DAC analogue
lacks that albumin-binding maleimido functionality. It should
therefore not be described as the same molecule with merely a shorter
“half-life setting.” It is a different chemical form whose
identity must be stated explicitly.

The naming problem: “CJC-1295 No DAC” is not
the original literature name

The 2005
Endocrinology paper uses CJC-1295 for the DAC-containing compound.
Commercial catalogues often use “CJC-1295 No DAC” for a modified
GRF(1-29)-type peptide. That convention can be useful for navigation,
but it is not sufficient for analytical identity.

For procurement and
documentation, record the sequence or formal chemical description
supplied for the exact material. If a supplier lists only “CJC-1295,”
clarify whether the DAC functionality is present before comparing
expected mass or literature behaviour.

What the kinetic literature can legitimately
support

Human CJC-1295
studies reported prolonged concentrations and endocrine effects for
the DAC-containing compound. Those observations establish a property
of the investigated compound and study design; they are not a
protocol for an RUO material and should not be converted into dosing
intervals or administration schedules.

The Ionescu study is
also a useful correction to simplistic “continuous versus
pulsatile” claims: it reported that pulsatile GH secretion
persisted during continuous stimulation by CJC-1295. A comparison
page should therefore avoid invented claims that DAC necessarily
abolishes physiological pulsatility or causes receptor fatigue.

Laboratory comparison table: what actually needs
to match

Compare chemical
architecture first, then the analytical evidence. For the DAC entity,
the presence of the reactive albumin-binding group is part of
identity. For a no-DAC material, the absence of that group and the
exact modified GRF sequence/form must be resolved. HPLC and MS should
then be interpreted under their stated methods, not as
interchangeable evidence.

From Our Work: names do not release a batch

AbsoluteBioLab’s
approved batch-review workflow treats analytical evidence as a linked
set rather than as a single purity number. The review checks HPLC
purity/profile, MS identity, product and batch match, appearance,
labelled amount/content, water or moisture where applicable,
counter-ion information, document completeness and storage/handling
status. Analytical testing is produced by the manufacturer and/or
third-party laboratories; AbsoluteBioLab reviews that evidence. If a
meaningful mismatch remains unresolved, the batch is held while
clarification and/or a justified retest is requested. This does not
imply in-house analytical testing or laboratory accreditation.

That workflow is
particularly important for CJC-1295 naming. A familiar label cannot
substitute for product/batch match and identity evidence. Where the
stated form, expected mass and analytical record do not line up, the
correct action is clarification—not choosing the interpretation
that best fits the page title.

What this page does not decide

This comparison does
not tell a researcher which compound is “better,” does not
provide an administration schedule and does not extrapolate human
pharmacokinetic data into personal or veterinary use. It clarifies
two laboratory entities and the evidence needed to keep them
distinct.

Frequently asked questions

Is CJC-1295 No DAC the same molecule as CJC-1295
with DAC?

No. The
albumin-binding DAC functionality is a structural distinction.
Commercial “No DAC” naming should be resolved to an exact
modified GRF sequence/form before analytical or literature
comparisons.

Does DAC mean CJC-1295 is always non-pulsatile?

No. A human study
specifically reported persistence of pulsatile GH secretion during
continuous CJC-1295 stimulation. Simplistic “DAC equals
non-pulsatile” statements overstate the evidence.

Can retention time prove whether DAC is present?

Retention time can
support a method-specific comparison but is not a complete identity
proof. Expected molecular species and mass-spectrometric evidence are
stronger identity anchors.

Why keep the half-life information at all?

It explains why the
DAC was engineered and distinguishes the literature entities. It must
stay coupled to the studied compound and must not be converted into
administration guidance.

Key takeaway

Use chemical
identity to separate CJC-1295 with DAC from “No DAC” material.
The original CJC-1295 literature describes an albumin-binding
maleimido analogue; market naming should be confirmed by
sequence/form, expected mass, HPLC and MS before kinetic data are
interpreted.

References

1. Jette L, et al.
Human growth hormone-releasing factor (hGRF)1-29-albumin
bioconjugates activate the GRF receptor on the anterior pituitary in
rats: identification of CJC-1295 as a long-lasting GRF analog.
Endocrinology. 2005;146(7):3052-3058. DOI: 10.1210/en.2004-1286.
PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/

2. Teichman SL, et
al. Prolonged stimulation of growth hormone and IGF-I secretion by
CJC-1295, a long-acting analog of GHRH, in healthy adults. J Clin
Endocrinol Metab. 2006;91(3):799-805. DOI: 10.1210/jc.2005-1536.
PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/

3. Ionescu M,
Frohman LA. Pulsatile secretion of GH persists during continuous
stimulation by CJC-1295. J Clin Endocrinol Metab.
2006;91(12):4792-4797. DOI: 10.1210/jc.2006-1702. PMID: 17018654.
https://pubmed.ncbi.nlm.nih.gov/17018654/

4. Kubiak TM, et al.
Position 2 and position 2/Ala15-substituted analogs of bovine growth
hormone-releasing factor with enhanced metabolic stability. J Med
Chem. 1993;36(7):888-897. DOI: 10.1021/jm00059a014. PMID: 8464043.
https://pubmed.ncbi.nlm.nih.gov/8464043/

Publishing
notes — not visible article copy

Field	Instruction
SEO title	CJC-1295 DAC vs No DAC: Research Comparison
Meta description	Compare CJC-1295 with DAC and “No DAC” by chemical identity, albumin-binding design, analytical verification and research-model implications.
Canonical	https://absolutebiolab.com/laboratory-guides/science-compliance/cjc-1295-dac-vs-no-dac-half-life-kinetics/
Schema	Article + BreadcrumbList; add FAQPage only if the visible FAQ block is implemented exactly and no conflicting FAQ schema exists.
Journey stage	Consideration
Priority	P2
Primary image	O25_CJC1295_DAC_vs_No_DAC_Identity_Framework.png
Image alt	CJC-1295 DAC versus no-DAC identity framework comparing albumin-binding linker, sequence/form, HPLC profile, MS identity and batch evidence.
Image placement	After the opening answer, before the comparison table.
Internal vectors	C21 CJC-1295 No DAC + Ipamorelin product; C03 Growth Peptides catalogue; O36 growth-signalling comparison; C09 CoA portal.
Canonical / merge action	Use the half-life-kinetics URL as survivor: audit GSC shows 1 impression at average position 8 versus 0 impressions for /cjc-1295-dac-vs-no-dac-structural-kinetic-differences/. Transfer verified unique value from the duplicate and 301 it to this survivor after post-ID/canonical verification. Do not automatically redirect /cjc-1295-no-dac-research-context-and-naming/ in this job; report it because ownership overlaps C21 product identity.
Implementation boundary	Human pharmacokinetic publications are described only as literature context. No administration, dose, cycle or human/veterinary-use guidance.